A high concentration of MMP-2/gelatinase A and MMP-9/gelatinase B reduce NK cell-mediated cytotoxicity against an oral squamous cell carcinoma cell line

In Vivo

Volumn 22, Issue 5, 2008, Pages 593-598

  Lee, Bu Kyu ^a   Kim, Mi Jung ^a   Jang, Ha Soon ^a   Lee, Hee Ran ^a   Ahn, Kang Min ^a   Lee, Jong Ho ^b   Choung, Pill Hoon ^b   Kim, Myung Jin ^b  

^a University of Ulsan   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Immune escape; MMP 2; MMP 9; NK cell mediated cytotoxicity; Oral cancer

Indexed keywords

CHROMIUM 51; GELATINASE A; GELATINASE B; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUTH CARCINOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; TUMOR ESCAPE; TUMOR IMMUNITY;

EID: 53849145720     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. de Vicente JC, Fresno MF, Villalain L, Vega JA and Hernandez Vallejo G: Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol 41: 283-293, 2005.
2. Scully C and Bagan JV: Recent advances in oral oncology. Oral Oncol 43: 107-115, 2007.
3. Reinders J, Rozemuller EH, van der Ven KJ, Caillat-Zucman S, Slootweg PJ, de Weger RA and Tilanus MG: MHC class I chain-related gene a diversity in head and neck squamous cell carcinoma. Hum Immunol 67: 196-203, 2006.
4. Osaki T, Kimura T, Tatemoto Y, Yamamoto T and Yoneda K: Risk factors of metastasis in oral squamous cell carcinomas. Oncology 58: 137-143, 2000.
5. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W and Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492, 1996.
6. Kim MJ, Lee JC, Lee JJ, Kim S, Lee SG, Park SW, Sung MW and Heo DS: Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol 29(1): 28-34, 2008.
7. Kim S, Iizuka K, Aguila HL, Weissman IL and Yokoyama WM: In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 97: 2731-2736, 2000.
8. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC and Moretta L: Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 14: 619-648, 1996.
9. Lanier LL: NK cell receptors: Annu Rev Immunol 16: 359-393, 1998.
10. Sorsa T, Tjäderhane L and Salo T: Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 10(6): 311-318, 2004.
11. Overall CM and Kleifeld O: Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94(7): 941-946, 2006.
12. Myoung H, Kim MJ, Hong SD, Lee JI, Lim CY and Hong SP: Expression of membrane type I-matrix metalloproteinase in oral squamous cell carcinoma. Cancer Lett 185: 201-209, 2002.
13. Matsumoto H, Koga H, Iida M, Tarumi K, Fujita M and Haruma K: Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats. Scand J Gastroenterol 41(11): 1320-1329, 2006.
14. Mullberg J, Durie FH, Otten-Evans C, Alderson MR, Rose-John S, Cosman D, Black RA and Mohler KM: A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 155: 5198-5205, 1995.
15. Gallea-Robache S, Morand V, Millet S, Bruneau JM, Bhatnagar N, Chouaib S and Roman-Roman S: A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 9: 340-346, 1997.
16. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC and Lin RH: A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61: 237-242, 2001.
17. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro S D, Senior RM and Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411-422, 1998.
18. Zucker S, Lysik RM, Zarrabi MH and Moll U: M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53: 140-146, 1993.
19. Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, Kakeji, Y and Sugimachi K: Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 17: 2253-2258, 1997.
20. Torii A, Kodera Y, Uesaka K, Hirai T, Yasui K, Morimoto T, Yamamura Y, Kato T, Hayakawa T, Fujimoto N and Kito T: Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 84: 133-136, 1997.
21. Kawata R, Shimada T, Maruyama S, Hisa Y, Takenaka H and Murakami Y: Enhanced production of matrix metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node metastasis. Acta Otolaryngol 122: 101-106, 2002.
22. Ruokolainen H, Paakko P and Turpeenniemi-Hujanen T: Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 116: 422-427, 2005.
23. Ruokolainen H, Paakko P and Turpeenniemi-Hujanen T: Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma-tissue immunoreactivity predicts aggressive clinical course. Mod Pathol 19: 208-217, 2006.
24. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D, Beck S and Trowsdale J: Plasticity in the organization and sequences of human KIR/ ILT gene families. Proc Natl Acad Sci USA 97: 4778-4783, 2000.
25. Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E and Raulet DH: Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 3: 1142-1149, 2002.